IMC.AX - Immuron Limited

ASX - ASX Delayed Price. Currency in AUD
0.29
-0.00 (-1.69%)
At close: 3:58PM AEST
Stock chart is not supported by your current browser
Previous Close0.29
Open0.30
Bid0.29 x 0
Ask0.30 x 0
Day's Range0.29 - 0.30
52 Week Range0.14 - 0.60
Volume42,875
Avg. Volume398,629
Market Cap41.406M
Beta-1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.26
  • GlobeNewswire17 days ago

    Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

    Immuron Limited (ASX:IMC) (IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the successful completion of its colitis preclinical program at the University of Zürich, Switzerland. Immuron is pleased to report that oral administration of IMM-124E was successfully able to treat mice with immunologically induced colitis. In contrast to the results reported in April 2017 using an acute colitis model the latest results were generated in the T cell transfer model which utilizes immunodeficient mice which are deficient in functional B and T lymphocytes.

  • GlobeNewswirelast month

    Immuron CEO to Present at RedChip Global Online Growth Conference

    MELBOURNE, Australia, April 23, 2018-- Immuron Limited, Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the ...

  • GlobeNewswirelast month

    Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets

    US Travelan ® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales climbed to$ AUD501K, representing a strong 178% increase ...

  • GlobeNewswire2 months ago

    Immuron Announces A$5.1M Private Placement to U.S. Fund

    MELBOURNE, Australia, March 13, 2018--. Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for ...

  • GlobeNewswire2 months ago

    Immuron Progresses Discussions with Institutional Funds

    MELBOURNE, Australia, March 13, 2018-- Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for ...

  • GlobeNewswire2 months ago

    UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow

    MELBOURNE, Australia, March 13, 2018-- Australian microbiome biopharmaceutical company Immuron Limited is pleased to release to shareholders and investors its latest Company Presentation ahead of commencing ...

  • GlobeNewswire2 months ago

    Immuron Commences US Non-Deal Institutional Investor Roadshow

    MELBOURNE, Australia, March 12, 2018-- Australian microbiome biopharmaceutical company Immuron Limited is pleased to release to shareholders and investors its latest Company Presentation ahead of commencing ...

  • GlobeNewswire3 months ago

    Immuron Reports Positive Results in NASH Clinical Trial

    First-In Class Anti-LPS Mechanism of Action confirmed for IMM-124E Results demonstrate excellent safety and tolerability Statistically significant reduction in serum endotoxin/ Lipopolysaccharide levels ...

  • GlobeNewswire3 months ago

    Immuron Limited Issues Correction to Misleading Halt Announcement Headline

    MELBOURNE, Australia, March 07, 2018-- Immuron Limited wishes to correct a misleading halt announcement released over the wire yesterday.. The misleading statement was headed“ Immuron Ltd. ADR Halted ...

  • U.S. exchanges set for highest number of Asian IPOs since 2010
    Reuters7 months ago

    U.S. exchanges set for highest number of Asian IPOs since 2010

    U.S. exchanges are set to record their busiest year for IPOs from Asian firms since 2010 and may sustain the pace in 2018, as startups from Taiwan, Singapore, Indonesia and Vietnam join a flurry of Chinese firms that have already listed in the country. Chinese issuers have dominated U.S. IPO activity for several years, but Nasdaq and rival New York Stock Exchange (NYSE) have been increasingly targeting firms from fast-growing Southeast Asian economies and startups from Japan and Australia to counter their dependence on mainland companies.